Digital Transformation in Pharma: How GEO Is Reshaping the Entire Organization

The GEO Disruption Is Bigger Than Google, Yahoo, and Altavista

When search engines arrived in the early 2000s, they changed how people accessed information from companies. Generative Engine Optimization (GEO) and AI‑powered search are changing something more fundamental: instead of listing sources, these systems directly answer questions with what they assess to be the most relevant response.

Generative Engine Optimization (GEO) refers to how organizations shape the information that AI systems discover, select, synthesize, and present when answering user questions. Unlike traditional SEO—which optimizes visibility and ranking for clicks—GEO determines how content influences probabilistic, machine‑generated answers produced by tools such as ChatGPT, Perplexity, and Google’s AI Overviews. In this model, users may never see your website at all; they see an answer.

For pharma, that distinction is critical. Research consistently shows that the majority of patients now research their conditions and medications online before or after a physician visit¹. When that research increasingly happens through AI-powered tools like ChatGPT, Perplexity, or Google’s AI Overviews, the question is no longer just “Can patients find our content?” It becomes: “Does our content shape the answer the AI gives?”

Imagine the following: A patient types into an AI search tool: “What are the long-term cardiovascular risks of Drug XXX compared to alternatives?” The AI synthesizes an answer from dozens of sources. Your brand may not appear at all — or worse, may appear inaccurately. Who in your organization owns that answer? Right now, in most pharma companies, no one really does.

This is why GEO represents a bigger organizational challenge than SEO ever did. It does not just require new tactics. It requires every function to rethink its role.

Content & Engagement Functions

Marketing: The End of ‘Campaigns Only’

The campaign model — a burst of content tied to a launch or a congress — was already struggling. GEO accelerates its decline, showing that this is not enough. AI search systems reward content that is persistent, structured, and genuinely answers questions. Brands that build a sustainable library of credible, question-answering content will be surfaced. Brands that produce campaign bursts will be invisible.

That means pharma marketers must start answering the hard questions — including the uncomfortable ones about their own products’ limitations and risks, as these are the ones patients search online. Brands that avoid complexity will be replaced, in AI-generated answers, by sources that engage with nuance honestly. And don’t forget that even being market leader does not automatically secure AI visibility.

Crucially, this also means marketers must compliantly support customers all along their journey, not just at the moment of brand choice. Patients and HCPs have questions before diagnosis, after prescription, during treatment, and when problems arise. If brands only show up at launch or switch points, they abandon the majority of real‑world decision moments. In a GEO-driven world, relevance comes from continuously helping users navigate their reality — from understanding options, to managing expectations, to living with the therapy over time.

Medical Affairs: Patient Reality Over Academic Precision

Medical Affairs has an asset that is currently underused in GEO strategy: genuine clinical experience. AI search surfaces content that maps to real patient experience, not just clinical trial language². A publication written for HCPs or a congress abstract does not answer what a patient is actually asking.

Medical Affairs needs to move closer to patient-reported outcomes, real-world evidence, and the lived experience of disease — and translate that into structured, AI-discoverable content. AI is not looking for another academic presentation of conditions. It is sensitive to provide you a response that matches your context, your fears, your emotions. This is a different skill set from traditional medical publication or congress communication, and organizations need to build it deliberately.

MLR: The Volume Problem

GEO requires dramatically more content — and it has to be approved. Industry surveys consistently identify MLR cycle times as a leading bottleneck in pharma content operations³. Scale that problem by an order of magnitude, and the current model breaks.

AI-assisted review tools can help — but they introduce a new risk: AI reviewers tend to flag every element in isolation, producing exhaustive but sometimes misaligned feedback. Good human reviewers read a piece as a whole and calibrate corrections accordingly. MLR teams must define what good AI-assisted review looks like, what to accept, and where human judgment must prevail.

Governance & Risk Functions

Regulatory / OEC: From Individual Assets to Ecosystems

Pharmaceutical regulation has so far focused primarily on digital assets that are owned and directly sponsored by the company. GEO expands beyond this boundary by seeking to influence how external AI systems—over which pharma has no control and limited transparency—aggregate and present information.

Clear regulatory guidance for this model is still emerging. Until health authorities define formal expectations, it is the responsibility of Regulatory teams to establish internal guardrails, applying existing principles of accuracy and balance while proactively anticipating how future regulations are likely to evolve.

Legal: Mapping New Risk Territory

GEO introduces legal risk categories that most pharma legal teams have not yet mapped. These include: liability when AI synthesizes content inaccurately and contributes to patient harm. Scholars and legal practitioners are beginning to map this territory — the World Health Organization flagged AI-generated medical misinformation as a public health concern requiring regulatory response³. Legal must build mitigation strategies now, before case law defines the rules for them.

Infrastructure & Intelligence Functions

IT: Build for Flexibility, Not Certainty

The GenAI landscape is evolving faster than any previous technology cycle. Gartner’s 2024 Hype Cycle places multiple generative AI capabilities at or near peak expectations⁴, signaling rapid and unpredictable change ahead. IT needs to upgrade monolithic martech architectures to adapt to a moving target. The mandate is flexibility: enabling the business to experiment, learn, and pivot without multi-year implementation cycles.

Digital: The Measurement Problem

Measuring GEO impact is currently one of the most unsolved problems in digital marketing. Traditional metrics — impressions, sessions, click-through rates — do not capture whether a brand is being cited, recommended, or surfaced by AI systems. Digital teams must develop new measurement proxies: AI citation tracking, share-of-voice in AI answers, and structured data performance metrics. This is frontier work, and intellectual honesty about how much remains unknown is itself a strategic asset.

Market Access & HEOR: Evidence in the Age of AI Synthesis

AI is already changing how payers and HTA bodies access and synthesize evidence. This means a brand’s evidence package may be summarized and compared by an AI before any human reads it. HEOR and market access teams must ensure their evidence is structured to be machine-readable and accurately represented in AI synthesis — not just persuasive to a human committee.

The Integration Imperative

GEO does not have a functional home. It is not a marketing problem, a digital project, or a compliance issue. It is all of them simultaneously — and it requires the kind of cross-functional alignment that pharma has historically struggled to sustain.

The companies that will lead are those that create shared ownership of their content ecosystem across marketing, medical, regulatory, legal, IT, and market access — aligned around a single question:

Is your organization prepared for a world where AI answers patients’ questions before your brand does, with clear ownership, expertise, and guardrails?

References:

1. BCG (2026). Consumers Are Ready for AI-Enabled Health Care. Health Systems Need to Be, Too. Boston Consulting Group. https://www.bcg.com/publications/2026/consumers-are-ready-for-ai-health-care-are-systems
2. Building a Compliant Content Foundation for the Future. Veeva Systems Industry Report. Available at: https://www.veeva.com/resources/building-a-compliant-content-foundation-for-the-future/ Last accessed 05/05/2026
3. Ethics and governance of artificial intelligence for health: Guidance on large multi-modal models, World Health Organization, 25^th March 2025 https://www.who.int/publications/i/item/9789240084759 Last accessed 05/05/2026
4. Gartner 2024 Hype Cycle for Emerging Technologies Highlights Developer Productivity, Total Experience, AI and Security, https://www.gartner.com/en/newsroom/press-releases/2024-08-21-gartner-2024-hype-cycle-for-emerging-technologies-highlights-developer-productivity-total-experience-ai-and-security Last accessed 05/05/2026
5. Pharma Marketing in the Age of AI Search, Olivier Gryson

Olivier Gryson, PharmD, MSc
25 years of experience in digital marketing in the pharmaceutical industry
Special focus on AI Search in Pharma Marketing